THC and CBD killed pediatric brain tumor cells in the lab but did not improve survival in mouse models

THC and CBD induced dose-dependent cell death in medulloblastoma and ependymoma cell lines, with synergistic effects in combination. Mechanisms included cell cycle arrest, reactive oxygen species production, autophagy, and apoptosis. However, neither cannabinoids alone, in combination, nor combined with cyclophosphamide improved survival in orthotopic transplant models despite being well tolerated.

In vitro cytotoxicity, cell cycle, and mechanistic studies in medulloblastoma and ependymoma cell lines. In vivo orthotopic transplant models in mice for survival analysis. THC and CBD tested alone and in combination, and with the chemotherapy drug cyclophosphamide.

This study illustrates a critical gap in cancer cannabinoid research: laboratory cell-killing effects do not necessarily translate to meaningful tumor control in living organisms. It serves as a cautionary note against overinterpreting in vitro results.

The failure to translate in vitro effects to in vivo efficacy is a common problem in cancer drug development. This study emphasizes the importance of animal model testing before considering clinical trials, especially for vulnerable pediatric cancer patients.

Orthotopic models may not perfectly replicate human pediatric brain tumors. Only one combination ratio and dosing schedule tested. The blood-brain barrier may have limited cannabinoid delivery to tumors. Cell line results may not represent tumor heterogeneity.